Woulgan® Gel registered as a Class 1 exempt by the FDA in the USA

Biotec Pharmacon ASA’s (”Biotec”, OSE: BIOTEC) subsidiary Biotec Betaglucans has received positive confirmation by the FDA that Woulgan® Gel is listed as a Class 1 exempt in the USA

Woulgan® Gel is registered as a Class 1 exempt by the FDA in the USA. This means that Woulgan® can be imported and used in the country. However, in order to receive favourable reimbursement a more advanced classification will be needed and Biotec is currently working to clarify the optimal route and strategy.

The … continue reading »

Norwegian Minister of Trade and Industry Monica Mæland visits Biotec Pharmacon

(Tromsø, 23 February 2017)The Norwegian Minister of Trade and Industry has today visited Tromsø, to get feedback and to learn about the biotechnology activities of the Biotech North Cluster and to meet some of the local biotech companies. She also visited Biotec Pharmacon’s production facilities to see the company’s operation.

“We are very pleased that Mrs Mæland took the time to meet us in Tromsø. This was a great opportunity for Biotec Pharmacon and Biotech North to present some of the … continue reading »

Publication in Journal of Wound Care

Woulgan was recently featured in a scientific article in Journal of Wound Care:   Clinical evaluation of a bioactive beta-glucan gel in the treatment of ‘hard-to-heal’ wounds”.

“The aim of this evaluation is to assess the effects of a wound healing gel in a wounds of different  aetiologies. Data was recorded on the wound surface area, tissue type, and patient level of wound pain at baseline (0) and at weeks 1, 2, 3, 4, and 8. Of the total 39 patients enrolled in the … continue reading »

Biotec Pharmacon: Results for Q4 2016

(Tromsø, 2 February 2017) Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC) reported sales of NOK 18.2 million (13.1) in the fourth quarter of 2016, and a negative EBITDA of NOK 8.1 million (-7.1). Woulgan® generated sales of NOK 0.6 million during the fourth quarter and expects further sales growth going into 2017. ArcticZymes launched three new products, which will complement existing product offering in the market.

– With 39% sales growth in Q4 from Q4 2015 it is a boost for further … continue reading »

Invitation to presentation of Q4 2016 results

Biotec Pharmacon presents its report for the fourth quarter 2016 on Thursday, 2 February 2017. The presentation will be given by CEO Svein Lien and VP Marketing Woulgan Stuart Devine.

The presentation starts at 08:30 a.m. and will be in English.

Venue: Hotell Continental, Stortingsgata 24, Oslo.

The presentation can also be followed as a live webcast from Hegnar TV and it will be possible to post questions through the webcast console.

You can find the webcast here

The interim report for the fourth quarter 2016 … continue reading »

Updated Q&A

Biotec has as of 04.01.2017 updated it’s Q&A regarding Woulgan and the German reimbursement system

Biotec Pharmacon: Q3 2016 Results

(Tromsø, 25 October 2016) Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC) reported sales of NOK 21.1 million (16.4) in the third quarter of 2016, and a negative EBITDA of NOK 5.9 million (-3.5). Biotec continues to deliver on 2016 goals through ArcticZymes product expansion and confirmation of reimbursement by one of the largest insurance companies for two regions in Germany

We are very pleased with the progress we have seen in the last quarter. Good sales growth in both the beta-glucan and … continue reading »

First homecare customer in Germany

(Tromsø, 24 October 2016) Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC) continue to gain commercial traction in Germany by signing a supply agreement for Woulgan® with the first homecare provider.

In Germany, many patients’ wounds are treated by homecare providers offering walk-in wound care clinics and treatment in the patients’ home. The top homecare companies are large organizations with central purchasing functions which make them an efficient segment for Biotec to manage directly while the Company’s distributor Rogg Verbandstoffe GmbH& Co.KG. are … continue reading »